Benitec Biopharma Inc.
NASDAQ Capital MarketTotal Valuation
Benitec Biopharma Inc. carries a market capitalization of 272.97M, placing it among publicly traded companies globally. Its enterprise value stands at 302.03M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 272.97M |
| Enterprise Value | 302.03M |
Share Statistics
Benitec Biopharma Inc. currently has 34.35M shares outstanding.
| Shares Outstanding | 34.35M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.86 |
| P/TBV Ratio | 2.65 |
| P/FCF Ratio | -24.57 |
| P/OCF Ratio | -24.55 |
Financial Position
Benitec Biopharma Inc. maintains a current ratio of 56.82, meaning it holds 56.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 56.82 |
| Quick Ratio | 56.43 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -33.46 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Benitec Biopharma Inc.'s stock has declined approximately -32.85991% over the past 52 weeks. The 50-day moving average sits at 11.75, while the 200-day moving average is 12.68.
| Beta (5Y) | N/A |
| 52-Week Price Change | -32.85991% |
| 50-Day Moving Average | 11.75 |
| 200-Day Moving Average | 12.68 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -53.46M, while operating income came in at -53.94M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -53.94M |
| Pretax Income | -48.88M |
| Net Income | -48.88M |
| EBITDA | -53.46M |
| EBIT | -53.94M |
| Earnings Per Share (EPS) | -1.07 |
Balance Sheet
Benitec Biopharma Inc. holds 184.76M in cash and equivalents against 876,000.00 in total debt, resulting in a net debt position of -184.76M. Total book value stands at -260.91M, with working capital of 182.74M providing operational flexibility.
| Cash & Cash Equivalents | 184.76M |
| Total Debt | 876,000.00 |
| Net Debt | -184.76M |
| Equity (Book Value) | -260.91M |
| Book Value Per Share | -5.72 |
| Working Capital | 182.74M |
Cash Flow
Benitec Biopharma Inc. produced -19.79M in operating cash flow over the past twelve months. After subtracting -15,000.00 in capital expenditures, free cash flow totaled -19.81M - equivalent to -0.43 per share.
| Operating Cash Flow | -19.79M |
| Capital Expenditures | -15,000.00 |
| Free Cash Flow | -19.81M |
| FCF Per Share | -0.43 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -20.84 |
| FCF Yield | -4.07 |
Stock Splits
Benitec Biopharma Inc.'s most recent stock split took place on July 26, 2023 with a 17:1 split ratio.
| Last Split Date | 7/26/2023 |
| Split Ratio | 17:1 |
Scores
Benitec Biopharma Inc. posts an Altman Z-Score of 77.75, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 77.75 |